Similarly, resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) is often caused by an EGFR T790M mutation that restores ATP affinity and reduces drug binding. Here, EGFR is linked to non-small cell lung carcinoma.